Observational studyBMC musculoskeletal disorders2025
One shot of hyaluronic acid in advanced knee osteoarthritis: postmarketing clinical follow-up for real-world evidence in a pain unit.
Observational study in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Clinical efficacy of intra-articular sodium hyaluronate injection and optimizing the puncture site in knee osteoarthritis.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundthis study aims to assess the real-world efficacy and safety of one shot of intraarticular (IA) hyaluronic acid (HA) in patients with advanced knee osteoarthritis (OA), in accordance with the requirement of the new EU Regulation on medical devices to monitor the safety and efficacy of throughout their life cycle.
methodsobservational, cross-sectional and retrospective study in a cohort of patients with advanced knee OA treated in a Pain Unit with a single injection of IA HA between January 2021 and December 2022. Efficacy was assessed at 6 months using the Visual Analogue Scale (VAS) for pain, and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for pain, stiffness and function. The Research Ethics Committee of the Autonomous Community of Aragon (CEICA) approved the study. Patient's data were pseudonymized.
resultsthe study included a cohort of 30 patients (mean age 73.1, 63.3% female, 66.7% retired). At 6 months, patients showed 51.3% and 52.2% reduction in pain (VAS and WOMAC, respectively), 44.9% improvement in function and 60% improvement in stiffness. In addition, 83.3% of patients showed improvement ≥ 20% according to VAS and 80% of patients according to total WOMAC. No adverse events were informed.
conclusionthe results support the use of IA HA as an effective and safe treatment for advanced knee OA, providing significant improvements in pain, stiffness, and function over six months. Future research should include larger populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.